These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21239814)

  • 1. Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.
    Cutler C
    Hematology Am Soc Hematol Educ Program; 2010; 2010():325-9. PubMed ID: 21239814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.
    Cremers EM; van Biezen A; de Wreede LC; Scholten M; Vitek A; Finke J; Platzbecker U; Beelen D; Schwerdtfeger R; Volin L; Harhalakis N; Blijlevens N; Nagler A; Kröger N; de Witte T
    Ann Hematol; 2016 Dec; 95(12):1971-1978. PubMed ID: 27650829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
    Oran B
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S43-9. PubMed ID: 26297277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
    Mishra A; Anasetti C
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S49-52. PubMed ID: 27521324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review.
    Parmar S; de Lima M; Deeg HJ; Champlin R
    Semin Oncol; 2011 Oct; 38(5):693-704. PubMed ID: 21943676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.
    Lee JH; Lee JH; Lim SN; Kim DY; Kim SH; Lee YS; Kang YA; Kang SI; Jeon MJ; Seol M; Seo EJ; Chi HS; Park CJ; Jang S; Yun SC; Lee KH
    Bone Marrow Transplant; 2010 Mar; 45(3):450-7. PubMed ID: 19668236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia.
    Cutler C
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):77-81. PubMed ID: 25696838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplants in myelodysplastic syndromes.
    Wetzko K; Platzbecker U
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1011-22. PubMed ID: 25459176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation for myelodysplastic syndrome.
    Barrett AJ; Savani BN
    Semin Hematol; 2008 Jan; 45(1):49-59. PubMed ID: 18179969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes.
    Kröger N
    Semin Hematol; 2017 Jul; 54(3):154-158. PubMed ID: 28958289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions.
    Warlick ED
    Curr Opin Oncol; 2010 Mar; 22(2):150-4. PubMed ID: 20010295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplant for MDS: challenges and emerging strategies.
    Tamari R; Castro-Malaspina H
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):43-54. PubMed ID: 25659729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?
    Brierley CK; Steensma DP
    Curr Opin Hematol; 2016 Mar; 23(2):167-74. PubMed ID: 26717194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?
    Sohn SK; Moon JH
    Expert Rev Hematol; 2013 Aug; 6(4):389-95. PubMed ID: 23991925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
    de Lima M; Giralt S
    Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hematopoietic cell transplantation as therapy for myelodysplasia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):541-7. PubMed ID: 22127318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of pre-transplant debulking treatment in patients undergoing allogeneic stem cell transplantation for high-risk myelodysplastic syndrome].
    Gauthier J; Damaj G; Yakoub-Agha I
    Bull Cancer; 2015 Apr; 102(4):340-8. PubMed ID: 25799164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.